Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 4Neoplasms 4Lung Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Weight Loss 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Recurrence 2Myasthenia Gravis 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma 2Cachexia 2Anorexia 2

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Laryngeal Diseases × 30 days × Clear all
NCT06788990 2026-06-02

FORTIFI-HN01

Bicara Therapeutics

Phase 2/3 Recruiting
650 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡